FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | | 2. 股份分類 | 其他分類 (請註明) | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 ...

FF305 第 2 頁 共 6 頁 v 1.3.0 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年2月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年2月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | | 已發行股份 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年1月24 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向五名承授人授出可認購 合共9,073股美國存託股份的購股權並向二百七十五名承授人授出涉及合共99,670 股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2025年1月24日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予五名 承授人可認購合共9,073股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： | 授出日期： | 2025年1月24日 | | --- | --- | | 承授人數目： | 五名 | | 已授出購股權涉及的相關股份數目： | 117,949 | | 購股權總數（美國存 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$208.22, representing a potential upside of 76% from the current price of HK$118.20 [3][4]. Core Insights - The company is advancing towards profitability by enhancing its market position and R&D capabilities, with a focus on reducing drug development costs through an internal clinical team [1][2]. - The company has a robust pipeline with significant potential, including key commercial products and a strong internal R&D pipeline consisting of 25 Phase I projects, 8 Phase II projects, and 7 Phase III projects [2][5]. - Financial performance is improving, with expectations of positive GAAP operating profit in 2025, driven by effective cost control and a reduction in reliance on CROs [2][5]. Summary by Sections Investment Rating - The company is rated as "Buy" with a target price of HK$208.22, corresponding to a 5.8x sales multiple for 2025 [3][4]. Market Position and R&D Strength - The company has established a global internal clinical development team of 3,600 members, significantly reducing reliance on CROs from 77% in 2019 to 5% in 2024 [1]. - Strategic focus areas for 2025 include consolidating leadership in hematology, accelerating internal pipeline development, and enhancing financial performance [1]. Pipeline and Product Potential - The key commercial product, Zebutini, is the first BTK inhibitor in the U.S. and shows excellent efficacy in treating blood cancers [2]. - The company’s pipeline includes high-potential early-stage candidates such as CDK4i and panKRASi, which are expected to drive future growth [2]. Financial Performance - In Q2 2024, the company achieved Non-GAAP profitability, and by Q3 2024, it recorded positive operating cash flow for the first time [2]. - The company forecasts a positive GAAP operating profit for the full year of 2025, supported by effective cost management strategies [2][5]. Key Financial Data - Projected revenues are expected to grow from US$2,459 million in 2023 to US$4,904 million in 2025, with a net profit turning positive in 2025 at US$137 million [4][12]. - The company’s gross profit is projected to increase from US$2,080 million in 2023 to US$3,857 million in 2025, indicating strong growth potential [4][12].

A 股代码：688235 A 股简称：百济神州 公告编号：2025-002 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于 2025 年第一次临时股东大会（股东特别大会） 股权登记日的公告 本公司董事会及全体董事保证公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性依法承担法律责任。 重要内容提示： 1、百济神州有限公司（以下简称"公司"）于 2024 年 9 月 21 日在上海证券交易所网站披露了《百济神州有限公司关于 2024 年第一次临时股东大会（股东特别大会）股权登记日的公 告》（公告编号：2024-022），该公告所载公司 2024 年第一次 临时股东大会（股东特别大会）的股权登记日为 2024 年 10 月 8 日。因 2024 年第一次临时股东大会（股东特别大会）未能在 2024 年度召开，现公司将会议届次相应调整为 2025 年第一次临时股 东大会（股东特别大会）（以下简称"2025 年股东特别大会"）， 并根据公司注册地法律及各股票上市地规则的规定将 2025 年股 东特别大会的股权登记日确定为 2025 年 2 月 ...

Investment Rating - The report maintains a "Buy" rating for the company's US and Hong Kong stocks, and upgrades the A-share rating to "Buy" [3][10]. Core Insights - The company has provided its first-ever guidance on profitability, expecting to achieve GAAP operating profit breakeven in 2025. This guidance has positively impacted market sentiment, leading to stock price increases across all markets [3][10]. - The target prices have been raised to USD 268 for US stocks, HKD 161 for Hong Kong stocks, and CNY 197 for A-shares, reflecting an expected upside of 45%, 40%, and 10% respectively [3][10][8]. Financial Performance and Projections - The company reported revenues of USD 1,416 million in 2022, with projections of USD 2,459 million in 2023, USD 3,696 million in 2024, USD 4,689 million in 2025, and USD 5,346 million in 2026, indicating a compound annual growth rate (CAGR) of 20.4%, 73.7%, 50.3%, 26.9%, and 14.0% respectively [11][15]. - The net loss attributable to shareholders is projected to decrease from USD 2,004 million in 2022 to a profit of USD 57 million in 2025 and USD 199 million in 2026 [11][15]. Market Position and Product Pipeline - The company holds a strong position in the CLL market, with its core product, Zebrutinib, capturing approximately 50% of the new patient market share [4]. - The company is advancing two next-generation hematologic cancer products, with significant clinical trial milestones expected in 2025 [5][6]. Research and Development Efficiency - The company demonstrates strong execution capabilities, with an average time of 8-9 months from GLP toxicology studies to first-in-human trials, which is 30% faster than industry standards [6]. - The clinical team is expected to grow from over 3,000 to 3,600 by the end of 2024, enhancing the company's research and development efficiency [6]. Valuation Metrics - The report indicates a price-to-sales (P/S) ratio of 13.9 in 2022, decreasing to 3.7 by 2026, reflecting improved revenue generation relative to market valuation [11][15]. - The projected operating margin is expected to improve significantly, with a breakeven point anticipated in 2025 [10].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百济神州有限公司（以下简称"公司"）于近日宣布，公司在纳斯达克交 易的美国存托股份的股票代码将由"BGNE"变更为"ONC"，自 2025 年 1 月 2 日起生效，以彰显公司在全球范围内致力于提供创新肿瘤药物的坚定承诺。 公司在上海证券交易所的股票代码及证券简称和香港联合交易所有限公司 的股票代码及证券简称保持不变。纳斯达克股票代码变更无需提交公司股东大 会审议即可实施。 公司将根据相关事项的进展情况及时履行信息披露义务，敬请广大投资者 注意投资风险。 A 股代码：688235 A 股简称：百济神州 公告编号：2024-031 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 自愿披露关于变更公司纳斯达克股票代码的公告 特此公告。 百济神州有限公司董事会 2024 年 12 月 24 日 1 ...

Summary of BeiGene's Investor Webcast Company Overview - **Company**: BeiGene - **Industry**: Pharmaceutical/Biotechnology - **Focus**: Oncology and Hematology Key Points from the Call R&D Strategy and Portfolio Evolution - The pharmaceutical industry faces challenges such as long development timelines, high costs, and low success rates [6][7] - BeiGene emphasizes early-stage investment and clinical proof of concept (POC) as critical for success [7][8] - The company aims to develop combination therapies early to reduce competition and enhance treatment efficacy [9] - Maintaining discipline in late-stage development is essential to avoid over-investment in non-transformative medicines [10] Clinical Development Highlights - BeiGene has invested in technology platforms and drug discovery, leading to a robust oncology-focused discovery team [10][11] - The company is close to completing enrollment for its Phase III CELESTIAL trial with approximately 640 patients enrolled in one year [11] - Significant advancements in drug development include 29 small molecule programs, with 14 being CDAC protein degraders [13] - The company has expanded its research capabilities, resulting in 16 novel molecules entering the clinic in the past 18 months [15] Solid Tumor Pipeline - The CDK4 selective inhibitor, BGB-437395, is central to BeiGene's breast cancer franchise, with ongoing trials and promising early data [17][30] - The company is exploring the use of CDK4 and CDK2 inhibitors in gynecologic malignancies [19] - The Phase 1a study of BGB-437395 has enrolled over 120 patients, focusing on safety and pharmacokinetics [20][30] Hematology Programs - **Brukinza (Zanubrutinib)**: A leading BTK inhibitor with broad approval and high market access, showing superiority over other BTK inhibitors [35][41] - **Sonorotoclax**: A BCL-2 inhibitor with promising efficacy data, currently in advanced development stages [36][77] - The company has enrolled over 1,600 patients in the BCL-2 program, demonstrating compelling efficacy [36] - The BTK degrader program has enrolled more than 400 patients, showing strong clinical data, particularly in BTK-resistant CLL [38] Recent Conference Presentations - BeiGene presented 21 abstracts at the ASH conference, showcasing its commitment to generating data for physicians and patients [42] - The SEQUOIA study demonstrated sustained efficacy and safety for Brukinza in frontline CLL patients [58] - The AMPLIFY study did not meet expectations, highlighting the need for safe and effective fixed-duration treatments [67][71] Future Outlook - BeiGene plans to initiate Phase III studies for its CDK4 inhibitor and continue expanding its hematology portfolio [32][80] - The company aims to address unmet needs in multiple myeloma and acute myeloid leukemia with new drug candidates [80] Additional Important Insights - The company is leveraging AI and automation to improve clinical trial efficiency [12] - BeiGene's internalized clinical operation model offers significant cost and speed advantages [11] - The focus on combination therapies and innovative drug modalities positions BeiGene as a leader in the oncology space [9][10]